[1] STERN RS, DIVITO SJ.Stevens-Johnson syndrome and toxic epidermal necrolysis: association, outcomes, and pathobiology-thirty years of progress but still much to be done[J]. J Invest Dermatol, 2017, 137(5): 1004-1008. [2] SEKULA P, DUNANT A, MOCKENHAUPT M, et al.Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. J Invest Dermatol, 2013, 133(5): 1197-1204. [3] SCHWARTZ RA, MCDONOUGH PH, LEE BW. Toxic epidermal necrolysis: part I. introduction, history, classification, clinical features, systemic manifestations, etiology,immunopathogenesis[J]. J Am Acad Dermatol, 2013, 69(2): 173.e1-13. [4] SOTOZONO C, UETA M, NAKATANI E, et al.Predictive factors associ-ated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. Am J Ophthalmol, 2015, 160(2): 228-237. [5] SCHWARTZ RA, MCDONOUGH PH, LEE BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention,treatment[J]. J Am Acad Dermatol, 2013, 69(2): 187.e1-16. [6] JANOUK D, SIMONE C, CHIARA G, et al.Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry[J]. Pharmacoepidemiol Drug Saf, 2015, 25(2): 196-203. [7] MOCKENHAUPT M, VIBOUD C, DUNANT A, et al.Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. TheRuroSCAR-study[J]. J Invest Dermatol, 2008, 128(1): 35-44. [8] GOLDMAN JL, CHUNG WH, LEE BR, et al.Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement[J]. Eur J Clin Pharmacol, 2019, 75(8): 1135-1141. [9] SASSOLAS B, HADDAD C, MOCKENHAUPT M, et al.ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case control analysis[J]. Clin Pharmacol Ther, 2010, 88(1): 60-68. [10] PEI Y, WANG R, WANG DD, et al.Literature analysis of HLA-B*5801 polymorphisms and cutaneous adverse reactions induced by allopurinol[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(3): 154-156. [11] LI X, YU K, MEI S, et al.HLA-B *1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson syndrome/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies[J]. Drug Res (Stuttg), 2015, 65(2): 107-111. [12] KHALAF D, TOEMA B, DABBOUR N, et al.Toxic epidermal necrolysis associated with severe cytomegalovirus infection in a patient on regular hemodialysis[J]. Mediterr J Hematol Infect Dis, 2011, 3(1): e2011004. [13] LERCH M, MAINETTI C, TERZIROLI B, et al.Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. Clin Rev Allergy Immunol, 2018, 54(1): 147-176. [14] WU XF, LIN Z, LI Y, et al.Retrospective analysis of 346 cases of drug eruptions[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(3): 149-153. [15] MA ZT, GONG R, FU NS, et al.Death due to serious toxic epidermal necrolysis evoked by cefoperazone sodium and sulbactam sodium[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2017, 19(2): 127-129. [16] LEE HY, Tharmotharampillai T, Pang SM, et al.Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in adults[J]. Int J Dermatol, 2017, 56(4): e78-e79. [17] AMSTUTZ U, SHEAR NH, RIEDER MJ, et al.Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions[J]. Epilepsia, 2014, 55(4): 496-506. [18] SAITO Y, STAMP LK, CAUDLE KE, et al.Clinical Pharmaco-genetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update[J]. Clin Pharmacol Ther, 2016, 99(1): 36-37. |